SRPT: Sarepta Therapeutics Inc. (DE) Stocks News on April 19, 2025

Exploring 3 High Growth Tech Stocks In The US Market

SRPT

Simply Wall St.

a day ago

Exploring 3 High Growth Tech Stocks In The US Market

SRPT

MT Newswires

2 days ago

BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating

SRPT

Simply Wall St.

2 days ago

Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week

SRPT

Zacks

3 days ago

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT

StockStory

3 days ago

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT

Argus Research

4 days ago

SRPT: Raising target price to $44.00

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

SRPT

Business Wire

4 days ago

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

SRPT

MT Newswires

8 days ago

Wells Fargo Initiates Sarepta Therapeutics at Overweight With $115 Price Target

SRPT

Zacks

9 days ago

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

SRPT

Zacks

10 days ago

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

SRPT

Argus Research

11 days ago

SRPT: Lowering target price to $39.00

SRPT

StockStory

11 days ago

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead

SRPT

MT Newswires

12 days ago

Oppenheimer Adjusts Price Target on Sarepta Therapeutics to $184 From $215, Keeps Outperform Rating

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

SRPT

Motley Fool

12 days ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Sarepta and Roche aim to resume paused Elevidys trials following patient death

SRPT

Clinical Trials Arena

12 days ago

Sarepta and Roche aim to resume paused Elevidys trials following patient death

Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death

SRPT

Investopedia

15 days ago

Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death

SRPT

MT Newswires

15 days ago

Sarepta Says EU Regulators Temporarily Halt Enrollment, Dosing in Elevidys Trials

Sarepta price target lowered to $183 from $202 at Needham

SRPT

TipRanks

15 days ago

Sarepta price target lowered to $183 from $202 at Needham

Sarepta Therapeutics Provides Update on ELEVIDYS

SRPT

Business Wire

15 days ago

Sarepta Therapeutics Provides Update on ELEVIDYS

SRPT

Zacks

15 days ago

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy

SRPT

Investor's Business Daily

16 days ago

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

SRPT

Benzinga

16 days ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

SRPT

MT Newswires

16 days ago

Sarepta Shares Fall After EMA Reportedly Places Hold on Elevidys Trial Enrollment for Duchenne Muscular Dystrophy

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death

SRPT

Investor's Business Daily

16 days ago

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death

SRPT

MT Newswires

16 days ago

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $70 From $99, Maintains Hold Rating

Roche halts testing of Sarepta Duchenne gene therapy in Europe

SRPT

BioPharma Dive

16 days ago

Roche halts testing of Sarepta Duchenne gene therapy in Europe

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

SRPT

StockStory

16 days ago

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

SRPT

MT Newswires

17 days ago

Sarepta Therapeutics Shares Rise After HC Wainwright Upgrade

SRPT

MT Newswires

17 days ago

HC Wainwright Upgrades Sarepta Therapeutics to Neutral From Sell, Price Target is $75

SRPT

Argus Research

18 days ago

SRPT: Lowering target price to $50.00

Sarepta price target lowered to $179 from $210 at BofA

SRPT

TipRanks

18 days ago

Sarepta price target lowered to $179 from $210 at BofA

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

SRPT

TipRanks

18 days ago

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

Biotech stocks slide as Marks resignation seen being negative for sector

SRPT

TipRanks

18 days ago

Biotech stocks slide as Marks resignation seen being negative for sector

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPT

Business Wire

19 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

SRPT

Investor's Business Daily

19 days ago

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

SRPT

StockStory

19 days ago

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving

SRPT

MT Newswires

19 days ago

Sarepta Therapeutics Faces Uncertainty Amid FDA Changes, Patient Death, RBC Says

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

SRPT

The Wall Street Journal

19 days ago

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns

SRPT

Investor's Business Daily

19 days ago

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out

SRPT

The Wall Street Journal

19 days ago

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out

SRPT

MT Newswires

19 days ago

RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161

SRPT

Insider Monkey

21 days ago

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?

SRPT

Zacks

22 days ago

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

SRPT

Argus Research

25 days ago

SRPT: What does Argus have to say about SRPT?

SRPT

Zacks

a month ago

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

SRPT

StockStory

a month ago

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

SRPT

Motley Fool

a month ago

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

SRPT

StockStory

a month ago

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

SRPT

Zacks

a month ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

SRPT

Zacks

a month ago

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

SRPT

Zacks

a month ago

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?

SRPT

Insider Monkey

a month ago

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?

SRPT

Zacks

a month ago

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

SRPT

Insider Monkey

a month ago

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?

SRPT

Zacks

a month ago

Company News for Mar 19, 2025

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.

SRPT

Investor's Business Daily

a month ago

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.

SRPT

MT Newswires

a month ago

Sector Update: Health Care

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

SRPT

Benzinga

a month ago

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies

SRPT

Investor's Business Daily

a month ago

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies

SRPT

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

SRPT

Simply Wall St.

a month ago

Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $82.00

SRPT

StockStory

2 months ago

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Sarepta price target lowered to $210 from $217 at BofA

SRPT

TipRanks

2 months ago

Sarepta price target lowered to $210 from $217 at BofA

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

SRPT

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Sarepta Therapeutics Inc Earnings Call

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

SRPT

Zacks

2 months ago

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

SRPT

MT Newswires

2 months ago

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $124 From $136, Maintains Hold Rating

SRPT

MT Newswires

2 months ago

RBC Trims Price Target on Sarepta Therapeutics to $161 From $165, Keeps Outperform Rating

SRPT

MT Newswires

2 months ago

Morgan Stanley Lifts Price Target on Sarepta Therapeutics to $196 From $195, Keeps Overweight Rating

SRPT

GuruFocus.com

2 months ago

Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

SRPT

Motley Fool

2 months ago

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript

SRPT

Zacks

2 months ago

Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Q4 Non-GAAP Earnings, Revenue Rise

SRPT

Insider Monkey

2 months ago

Sarepta Therapeutics, Inc. (SRPT): Among the Stocks That Will Go to The Moon According to Analysts

SRPT

StockStory

2 months ago

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

SRPT

Insider Monkey

2 months ago

Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $84.00

SRPT

Zacks

2 months ago

Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Closes $600 Million Revolving Credit Facility

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

SRPT

Business Wire

2 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

SRPT

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

SRPT

MT Newswires

2 months ago

Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Hold Rating, $136 Price Target

SRPT

MT Newswires

2 months ago

Arrowhead Closes Licensing, Collaboration Agreement With Sarepta

2 Growth Stocks to Buy Hand Over Fist in February

SRPT

Motley Fool

2 months ago

2 Growth Stocks to Buy Hand Over Fist in February

SRPT

Insider Monkey

2 months ago

Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts

Nvidia And 2 Other High Growth Tech Stocks In The United States

SRPT

Simply Wall St.

2 months ago

Nvidia And 2 Other High Growth Tech Stocks In The United States

SRPT

Zacks

2 months ago

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $91.00

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

SRPT

Zacks

3 months ago

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

SRPT

Insider Monkey

3 months ago

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’

Sarepta could be down on patient death in FDA database, says RBC Capital

SRPT

TipRanks

3 months ago

Sarepta could be down on patient death in FDA database, says RBC Capital

SRPT

Argus Research

3 months ago

SRPT: Raising target price to $94.00

SRPT

MT Newswires

3 months ago

Sarepta Therapeutics Says Phase 3 Study of Potential Muscular Dystrophy Drug Shows 'Positive' Results

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

SRPT

Business Wire

3 months ago

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

SRPT

Argus Research

3 months ago

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on April 19, 2025

Share on Social Networks: